West Pharmaceutical ServicesWST -0.67%95 Return-on-Tangible-Asset is 13.63% as of Mar. 2026, which is 3% above its 10-year median of 13.24. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $362.19 (Fairly Valued). The stock has 9 warning signs investors should review. Among 855 Medical Devices & Instruments companies, West Pharmaceutical Services ranks better than 90.53% on this metric.
The historical rank and industry rank for West Pharmaceutical Services's Return-on-Tangible-Asset or its related term are showing as below:
WST'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 9.07 Med: 13.24 Max: 22.69
Current: 13.94
During the past 13 years, West Pharmaceutical Services's highest Return-on-Tangible-Asset was 22.69%. The lowest was 9.07%. And the median was 13.24%.
WST's Return-on-Tangible-Asset is ranked better than 90.53% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.62
vs WST: 13.94
West Pharmaceutical Services (NYSE:WST) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
West Pharmaceutical Services Return-on-Tangible-Asset Related Terms
West Pharmaceutical Services Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services Return-on-Tangible-Asset Chart
WST vs RMD, MDLN, COO: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.63% mean?
West Pharmaceutical Services (WST) has a Return-on-Tangible-Asset of 13.63% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on West Pharmaceutical Services and its competitors. This is near median its historical median of 13.24. Over the past decade, West Pharmaceutical Services' Return-on-Tangible-Asset has ranged from 9.07 to 22.69. According to the industry distribution chart, West Pharmaceutical Services ranks #81 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 9.5%.
Is West Pharmaceutical Services' Return-on-Tangible-Asset too high?
West Pharmaceutical Services' current Return-on-Tangible-Asset of 13.63% is near median its 10-year median of 13.24. Over the past 10 years, this metric has ranged from a low of 9.07 to a high of 22.69. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. West Pharmaceutical Services' value of 13.63% is 2098.4% above this industry median. Based on the distribution chart, West Pharmaceutical Services ranks #81 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Return-on-Tangible-Asset compare to RMD and MDLN?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #81 out of 855 companies for Return-on-Tangible-Asset. This places West Pharmaceutical Services in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.62. West Pharmaceutical Services' value of 13.63% is 2098.4% above this benchmark. Historically, West Pharmaceutical Services' own Return-on-Tangible-Asset has ranged from 9.07 to 22.69 over the past decade. While the company's 10-year median is 13.24 vs. the industry median of 0.62, West Pharmaceutical Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. West Pharmaceutical Services's current Return-on-Tangible-Asset of 13.63% is 2098.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on West Pharmaceutical Services and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. West Pharmaceutical Services's current Return-on-Tangible-Asset is 13.63%, which is near median its own 10-year median of 13.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $362.19, compared to a current price of $353.68 — trading 2.3% below its estimated fair value. The current Return-on-Tangible-Asset is 13.63%, which is near median its 10-year median of 13.24 and 2098.4% above the Medical Devices & Instruments industry median of 0.62. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current Return-on-Tangible-Asset is 13.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is West Pharmaceutical Services (WST) Overvalued in 2026?
Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued.
The current stock price of $353.68 is trading 2.3% below its estimated GF Value™ of $362.19.
GuruFocus considers West Pharmaceutical Services to be Fairly Valued.
Key valuation signals for WST:
Return-on-Tangible-Asset: 13.63% (near median its 10-year median of 13.24)
GF Value™: $362.19 vs. price of $353.68 (2.3% below fair value)
Industry Position: 2098.4% above the Medical Devices & Instruments median (#81 of 855)
No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score
Get the complete analysis for WST
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WST has been successfully added to your 
